Skip to content

Daily Meditation Program in Women Admitted to the Antepartum Unit

Daily Meditation Program in Women Admitted to the Antepartum Unit: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03737279
Acronym
Meditate
Enrollment
56
Registered
2018-11-09
Start date
2019-03-04
Completion date
2020-04-01
Last updated
2020-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy, High Risk, Pregnancy Related

Keywords

Pregnancy, Meditation

Brief summary

The purpose of this study is to assess whether a daily mindful meditation program for women admitted to the antepartum floor will decrease maternal state anxiety compared to routine care.

Interventions

BEHAVIORALMeditation

Routine care + twice daily meditation per schedule, to start on the day of randomization

BEHAVIORALRoutine Care

Routine care including ACOG educational pamphlets: * Day 1: Nutrition in Pregnancy * Day 2: Heart Health for Women * Day 3: Exercise after Pregnancy

Sponsors

The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥ 18 years of age * ≥ 23.0 weeks gestation * Planned inpatient care for \> 3 days from randomization * Women cared for by UT physicians

Exclusion criteria

* Known major lethal fetal anomalies (eg. trisomy 13, trisomy 18, anencephaly, Potter's Syndrome) * Non-English speaking women * Planned delivery ≤ 3 days from randomization * Previous fetal surgery in the current pregnancy (twin twin transfusion syndrome laser ablation, spina bifida repair, etc) * Women who have practiced a form of meditation in the current pregnancy (including yoga) in the last 4 weeks * Women who are currently using patient-controlled analgesia (PCA) (eg. sickle cell crisis) * Admission diagnosis of ecclampsia or HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome * Diagnosed personality disorder including borderline personality disorder, histrionic personality disorder, schizoid personality disorder, schizotypal personality disorder, schizophrenia * Diagnosed anxiety, depression, bipolar or other psychiatric illness on medications for these disorders * Non-reassuring fetal heart tracing on admission * Intrauterine fetal demise at randomization * Inability to gain access to phone application

Design outcomes

Primary

MeasureTime frameDescription
Maternal state anxiety as assessed by the State Anxiety Scale1-3 daysThe State Anxiety Scale Ranges from 20 to 80, with higher scores indicating a higher anxiety level.

Secondary

MeasureTime frameDescription
Stress as assessed by the Perceived Stress Scale3 days to 11 weeks.The Perceived Stress Scale score ranges from 0 to 40, with higher scores indicating a higher stress level.
Depression as assessed by the Edinburgh Depression Scale3 days to 11 weeks.The Edinburgh Depression Scale score ranges from 0 to 30, with higher scores indicating a higher depression level.
Patient satisfaction3 days to 11 weeks.The Patient satisfaction questionnaire will be scored by a 5-point Likert Scale. Two questions will be asked relating to overall experience with the research trial and overall experience in the hospital. Each of the two questions will be rated with a 5-point Likert, with a total score ranging from 2 to 10 and with higher scores indicating a \[better/worse\] outcome.
Maternal state anxiety as assessed by the State Anxiety Scale1 to 11 weeks.The State Anxiety Scale score ranges from 20 to 80, with higher scores indicating a higher anxiety level.
Number of meditation sessions11 weeksMeditation sessions as reported per patient and documented by phone application.
Duration of meditation sessions11 weeksMeditation duration as reported per patient and documented by phone application.
Latency periodAt delivery.Latency period is defined as time from randomization until delivery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026